期刊
INVESTIGATIONAL NEW DRUGS
卷 37, 期 1, 页码 98-108出版社
SPRINGER
DOI: 10.1007/s10637-018-0614-9
关键词
Triple negative; hormone receptor and HER2 negative; advanced breast cancer; sonidegib; Hedgehog; docetaxel
资金
- Novartis Farmaceutica, S.A.
Up-regulation of the Hedgehog (Hh) pathway is implicated in the genesis of a wide range of tumors including triple negative breast cancer (TNBC). Sonidegib is a potent and selective oral inhibitor of Smo, a key component of the Hh signaling pathway. We designed a phase I clinical study to explore the combination of sonidegib plus docetaxel (fixed dose at 75mg/m(2)) in advanced TNBC patients. The primary objective was to ascertain the combination's maximum tolerated dose and the recommended phase II dose (RP2D), based on dose limiting toxicities (DLTs) in the first 2cycles. A standard 3+3 design was followed including three dose levels (DL) of sonidegib: 400mg (DL1), 600mg (DL2), and 800mg (DL3). Twelve patients were included. Sonidegib 800mg orally q.d. plus docetaxel 75mg/m(2) given intravenously on day 1 of 21-daycycles was established as the RP2D. No DLTs were observed at any DL. The median number of administered cycles at DL3 was 8 (range: 6 to 9). Grade 3 adverse events (AEs) at DL3 were neutropenia (66.7%), CPK increase (33.3%), leukopenia (33.3%), and paresthesia (33.3%), grade 4 AEs were not reported at this DL. At the RP2D, the combination showed antitumor activity in three out of 10 patients with measurable disease. Median time to progression for the overall study was 42.5days (95% Confidence Interval: 29-155), and 188days at DL3. No drug-to-drug interactions between sonidegib and docetaxel were found in the PK assessment. Trial Registration: EudraCT study number: 2013-001750-96. Study GEICAM/2012-12. TRIAL REGISTRATION: EudraCT study number: 2013-001750-96. Study GEICAM/2012-12. ClinicalTrials.gov: NCT02027376
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据